AI assistant
Protagonist Therapeutics, Inc — Director's Dealing 2018
Mar 3, 2018
31163_dirs_2018-03-02_e7e4eb9d-7ba7-423e-af59-fda6e74ca367.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Protagonist Therapeutics, Inc (PTGX)
CIK: 0001377121
Period of Report: 2018-02-28
Reporting Person: O'Neil Thomas P. (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-02-28 | Common Stock | A | 6000 | $0.00 | Acquired | 8858 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-02-28 | Stock Option (right to buy) | $16.95 | A | 34000 | Acquired | 2028-02-27 | Common Stock (34000) | Direct |
Footnotes
F1: Represents grant of the restricted stock units payable solely in common stock that vest in equal annual installments over four years from the grant date.
F2: Includes 1,572 shares and 1,286 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2017 and September 8, 2017, respectively.
F3: The shares underlying this option shall vest as to 25% after one year following the grant date, and the remainder will vest in equal monthly installments over the following three years.